trial

Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function

NCTId NCT00645580
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 15 (estimated)
Sponsored by Sha'ar Menashe Mental Health Center
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
15 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2008-04
Primary completion
2009-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Fluvoxamine

Sponsors

Sha'ar Menashe Mental Health CenterLead Sponsor

Investigators

1
Henry Silver, PhDPrincipal Investigator

Sites

1 total
Mobile Post Hefer, Israel

Facts & assertions

4 sourced
Enrollment
15
Phase
NA
Primary Completion Date
2009-04
Status
UNKNOWN
relationships
The graph out of here
drug
Fluvoxamine
drug
lead_sponsor
Sha'ar Menashe Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Henry Silver, PhD
person